OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Pantoprazole sodium is a proton pump inhibitor reduces stomach acid
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
For patients with resectable early-stage gastric and gastroesophageal junction cancers
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Subscribe To Our Newsletter & Stay Updated
